The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Gilead Sciences has completed its previously announced $4.9-billion acquisition of Forty Seven Inc., a Menlo Park, California-based clinical-stage immuno-oncology company. Gilead had announced the acquisition last month (March 2020).
Forty Seven’s...
The European Medicines Agency (EMA) is setting up a single-point-of-contact system with pharmaceutical companies for reporting drug shortage or potential drug shortages related to the novel coronavirus (COVID-19) outbreak.
The EMA reports...
Gilead Sciences and Second Genome, a microbiome clinical-stage company, have entered into a four-year collaboration worth up to $338 million ($38 million upfront and up to $300 million in milestones) to identify biomarkers associated with clinical...
The European Commission (EC) has outlined three measures it is taking to advise companies on how they may cooperate with each other in addressing potential drug shortages relating to the novel coronavirus (COVID-19) while maintaining compliance...
Danaher, a global science and technology company, headquartered in Washington D.C., has completed its $21.4-billion acquisition of the biopharma business from General Electric’s Life Sciences division. As part of Danaher, the business will be...
Sanofi forms COVID-19 vaccine research pact and advances clinical testing of antiviral. Bayer and AbbVie contribute to COVID-19 relief efforts. Gates Foundation contributes $1.73 million for antibody research.
Sanofi Advances Testing of...
Eli Lilly and Company and Sitryx, an Oxford, UK-based biopharmaceutical company focused on developing therapeutics in immuno-oncology and immuno-inflammation, have entered a licensing pact in a deal worth up to $880 million ($50 million...
Takeda has formed a licensing pact with Evox Therapeutics, an Oxford, UK-headquartered biopharmaceutical company, in a deal worth up to $882 million ($44 million upfront) for the development of protein-replacement and mRNA therapies.
The...
A roundup of developments from India (Bayer, GSK), the US (Boehringer Ingelheim, Lilly, Tetraphase, Amicus), and Japan (Amgen).
India
Bayer, Curadev Sign Agreement To Develop STING Antagonists Program Bayer and Curadev, a small-molecule...
Pfizer has completed a $1.25 billion, 10-year “sustainability” bond paying interest semi-annually of 2.625% and maturing April 1, 2030, which will be used to manage the company’s environmental and social impact. This is Pfizer’s first...
Johnson & Johnson (J&J) has selected a lead vaccine candidate against the novel coronavirus (COVID-19) for which it expects to initiate Phase I clinical studies by September 2020 and has established a manufacturing plan.
The company...
Daiichi Sankyo has formed a licensing pact with Ultragenyx Pharmaceutical, a biopharmaceutical company developing drugs for rare and ultra-rare genetic diseases, for the non-exclusive use of Ultragenyx’s adeno associated virus (AAV) based...
AbbVie has provided an update an its pending $63-billion acquisition of Allergan. The deal, which was announced in when, is expected to close in May 2020 pending approval by the US Federal Trade Commission (FTC).
AbbVie and Allergan have...
Roche has formed a research collaboration and option agreement with Forge Therapeutics, a San Diego-based biopharmaceutical company, under for Forge’s FG-LpxC lung, an antibiotic for treating serious lung infections attributed to...
AstraZeneca has formed a collaboration with Silence Therapeutics, a London-based biopharmaceutical, to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for treating cardiovascular, renal, metabolic and respiratory...
